Electronic data capture in resource-limited settings using the lightweight clinical data acquisition and recording system.
Sci Rep
2024
14
1
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.
Lancet Gastroenterol Hepatol
2024
9
8
734-744
Distinct metabolomic and lipidomic profiles in serum samples of patients with primary sclerosing cholangitis.
Front Med (Lausanne)
2024
11
Impact of telemedical management on hospitalization and mortality in heart failure patients with diabetes: a post-hoc subgroup analysis of the TIM-HF2 trial.
Cardiovasc Diabetol
2024
23
1
Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma.
Hepatology
2024
79
4
941-958
Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron-results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP).
Infection
2024
52
6
2253-2267
Pathogen spectrum of community acquired pneumonia in people living with HIV (PLWH) in the German CAPNETZ-Cohort.
Infection
2024
52
1
129-137
Resurgence of common respiratory viruses in patients with community-acquired pneumonia (CAP)-A prospective multicenter study.
J Clin Virol
2024
173
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
Lancet Gastroenterol Hepatol
2024
9
10
935-943
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).
J Cancer Res Clin Oncol
2024
150
10